Published in Nat Rev Cancer on June 04, 2015
Adenovirus-Mediated Somatic Genome Editing of Pten by CRISPR/Cas9 in Mouse Liver in Spite of Cas9-Specific Immune Responses. Hum Gene Ther (2015) 1.18
In vivo genome editing and organoid transplantation models of colorectal cancer and metastasis. Nat Biotechnol (2017) 1.04
CRISPR/gRNA-directed synergistic activation mediator (SAM) induces specific, persistent and robust reactivation of the HIV-1 latent reservoirs. Sci Rep (2015) 0.98
Creating and evaluating accurate CRISPR-Cas9 scalpels for genomic surgery. Nat Methods (2015) 0.96
Circadian Rhythm Disruption Promotes Lung Tumorigenesis. Cell Metab (2016) 0.90
Precision cancer mouse models through genome editing with CRISPR-Cas9. Genome Med (2015) 0.89
Cornerstones of CRISPR-Cas in drug discovery and therapy. Nat Rev Drug Discov (2016) 0.88
CRISPR: a versatile tool for both forward and reverse genetics research. Hum Genet (2016) 0.82
From Mice to Men and Back: An Assessment of Preclinical Model Systems for the Study of Lung Cancers. J Thorac Oncol (2015) 0.82
FGFR1 inhibition in lung squamous cell carcinoma: questions and controversies. Cell Death Discov (2015) 0.80
Development and potential applications of CRISPR-Cas9 genome editing technology in sarcoma. Cancer Lett (2016) 0.78
Mutational landscape of EGFR-, MYC-, and Kras-driven genetically engineered mouse models of lung adenocarcinoma. Proc Natl Acad Sci U S A (2016) 0.78
Genetically engineered mouse models in oncology research and cancer medicine. EMBO Mol Med (2016) 0.77
Tissue-specific tumorigenesis: context matters. Nat Rev Cancer (2017) 0.77
Genome editing: the road of CRISPR/Cas9 from bench to clinic. Exp Mol Med (2016) 0.77
The impact of chromatin dynamics on Cas9-mediated genome editing in human cells. ACS Synth Biol (2016) 0.77
Optimizing mouse models for precision cancer prevention. Nat Rev Cancer (2016) 0.77
High Efficiency CRISPR/Cas9-mediated Gene Editing in Primary Human T-cells Using Mutant Adenoviral E4orf6/E1b55k "Helper" Proteins. Mol Ther (2016) 0.77
Neutrophils: Critical components in experimental animal models of cancer. Semin Immunol (2016) 0.77
CRISPR applications in ophthalmologic genome surgery. Curr Opin Ophthalmol (2017) 0.76
CRISPR/Cas-mediated genome editing to treat EGFR-mutant lung cancer: a personalized molecular surgical therapy. EMBO Mol Med (2016) 0.76
Clustered Regularly Interspaced Short Palindromic Repeats/Cas9 Genetic Engineering: Robotic Genetic Surgery. Am J Robot Surg (2015) 0.76
Emerging Technologies to Create Inducible and Genetically Defined Porcine Cancer Models. Front Genet (2016) 0.76
The CRISPR road: from bench to bedside on an RNA-guided path. Ann Transl Med (2015) 0.75
An NgAgo tool for genome editing: did CRISPR/Cas9 just find a competitor? Genes Dis (2016) 0.75
Genetic disruption of oncogenic Kras sensitizes lung cancer cells to Fas receptor-mediated apoptosis. Proc Natl Acad Sci U S A (2017) 0.75
CRISPRdigger: detecting CRISPRs with better direct repeat annotations. Sci Rep (2016) 0.75
Novel Biological Approaches for Testing the Contributions of Single DSBs and DSB Clusters to the Biological Effects of High LET Radiation. Front Oncol (2016) 0.75
Nrf2-Dependent and -Independent Effects of tert-Butylhydroquinone, CDDO-Im, and H2O2 in Human Jurkat T Cells as Determined by CRISPR/Cas9 Gene Editing. J Pharmacol Exp Ther (2017) 0.75
CRISPR-Cas9: from Genome Editing to Cancer Research. Int J Biol Sci (2016) 0.75
Organoids as a Model for Colorectal Cancer. Curr Colorectal Cancer Rep (2016) 0.75
Androgen receptor mitigates postoperative disease progression of hepatocellular carcinoma by suppressing CD90+ populations and cell migration and by promoting anoikis in circulating tumor cells. Oncotarget (2016) 0.75
CRISPR/Cas9: Transcending the Reality of Genome Editing. Mol Ther Nucleic Acids (2017) 0.75
CRISPR-Cas Genome Surgery in Ophthalmology. Transl Vis Sci Technol (2017) 0.75
Rapid Generation of Human Genetic Loss-of-Function iPSC Lines by Simultaneous Reprogramming and Gene Editing. Stem Cell Reports (2017) 0.75
PHF6 regulates phenotypic plasticity through chromatin organization within lineage-specific genes. Genes Dev (2017) 0.75
Everything in moderation, even hype: learning from vaccine controversies to strike a balance with CRISPR. J Med Ethics (2017) 0.75
AAV-mediated direct in vivo CRISPR screen identifies functional suppressors in glioblastoma. Nat Neurosci (2017) 0.75
CRISPR/Cas9-Directed Reassignment of the GATA1 Initiation Codon in K562 Cells to Recapitulate AML in Down Syndrome. Mol Ther Nucleic Acids (2017) 0.75
The hallmarks of cancer. Cell (2000) 113.05
Multiplex genome engineering using CRISPR/Cas systems. Science (2013) 55.53
RNA-guided human genome engineering via Cas9. Science (2013) 48.29
A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. Science (2012) 48.17
Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature (2007) 37.09
A TALE nuclease architecture for efficient genome editing. Nat Biotechnol (2010) 26.47
Cancer genome landscapes. Science (2013) 25.33
One-step generation of mice carrying mutations in multiple genes by CRISPR/Cas-mediated genome engineering. Cell (2013) 24.00
Disruption of the proto-oncogene int-2 in mouse embryo-derived stem cells: a general strategy for targeting mutations to non-selectable genes. Nature (1988) 20.36
DNA targeting specificity of RNA-guided Cas9 nucleases. Nat Biotechnol (2013) 19.99
Highly efficient endogenous human gene correction using designed zinc-finger nucleases. Nature (2005) 19.15
Genome editing with engineered zinc finger nucleases. Nat Rev Genet (2010) 18.88
Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras. Genes Dev (2001) 15.97
RNA-programmed genome editing in human cells. Elife (2013) 14.82
Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med (2013) 14.78
Targeting DNA double-strand breaks with TAL effector nucleases. Genetics (2010) 14.49
Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers. Nat Med (2008) 14.47
Targeted genome engineering in human cells with the Cas9 RNA-guided endonuclease. Nat Biotechnol (2013) 14.28
Development and applications of CRISPR-Cas9 for genome engineering. Cell (2014) 13.50
Genome-scale CRISPR-Cas9 knockout screening in human cells. Science (2013) 12.36
Genetic engineering of human pluripotent cells using TALE nucleases. Nat Biotechnol (2011) 11.76
CAS9 transcriptional activators for target specificity screening and paired nickases for cooperative genome engineering. Nat Biotechnol (2013) 11.35
Genetic screens in human cells using the CRISPR-Cas9 system. Science (2013) 10.75
Genome editing. The new frontier of genome engineering with CRISPR-Cas9. Science (2014) 10.43
Oncogene-induced Nrf2 transcription promotes ROS detoxification and tumorigenesis. Nature (2011) 9.70
CRISPR-mediated modular RNA-guided regulation of transcription in eukaryotes. Cell (2013) 9.55
Targeted chromosomal cleavage and mutagenesis in Drosophila using zinc-finger nucleases. Genetics (2002) 9.09
Enhancing gene targeting with designed zinc finger nucleases. Science (2003) 8.42
One-step generation of mice carrying reporter and conditional alleles by CRISPR/Cas-mediated genome engineering. Cell (2013) 7.99
Insertion of DNA sequences into the human chromosomal beta-globin locus by homologous recombination. Nature (1985) 7.95
TALENs: a widely applicable technology for targeted genome editing. Nat Rev Mol Cell Biol (2012) 7.01
High frequency targeting of genes to specific sites in the mammalian genome. Cell (1986) 6.91
TAL nucleases (TALNs): hybrid proteins composed of TAL effectors and FokI DNA-cleavage domain. Nucleic Acids Res (2010) 6.65
Generation of gene-modified cynomolgus monkey via Cas9/RNA-mediated gene targeting in one-cell embryos. Cell (2014) 6.11
The differential effects of mutant p53 alleles on advanced murine lung cancer. Cancer Res (2005) 5.93
Genome editing with Cas9 in adult mice corrects a disease mutation and phenotype. Nat Biotechnol (2014) 5.71
Genome-Scale CRISPR-Mediated Control of Gene Repression and Activation. Cell (2014) 5.43
Maximizing mouse cancer models. Nat Rev Cancer (2007) 5.38
Expression of a site-specific endonuclease stimulates homologous recombination in mammalian cells. Proc Natl Acad Sci U S A (1994) 5.37
Genome-scale transcriptional activation by an engineered CRISPR-Cas9 complex. Nature (2014) 5.19
Tumor induction by an endogenous K-ras oncogene is highly dependent on cellular context. Cancer Cell (2003) 5.17
High-throughput screening of a CRISPR/Cas9 library for functional genomics in human cells. Nature (2014) 4.95
RNA-guided gene activation by CRISPR-Cas9-based transcription factors. Nat Methods (2013) 4.85
Genome-wide recessive genetic screening in mammalian cells with a lentiviral CRISPR-guide RNA library. Nat Biotechnol (2013) 4.72
CRISPR RNA-guided activation of endogenous human genes. Nat Methods (2013) 4.69
Orthogonal Cas9 proteins for RNA-guided gene regulation and editing. Nat Methods (2013) 4.61
Patient-derived models of acquired resistance can identify effective drug combinations for cancer. Science (2014) 4.34
Induction of homologous recombination in mammalian chromosomes by using the I-SceI system of Saccharomyces cerevisiae. Mol Cell Biol (1995) 3.96
Engineering complex synthetic transcriptional programs with CRISPR RNA scaffolds. Cell (2014) 3.76
CRISPR-Cas9 knockin mice for genome editing and cancer modeling. Cell (2014) 3.68
Genome-wide CRISPR screen in a mouse model of tumor growth and metastasis. Cell (2015) 3.58
Efficient genome engineering in human pluripotent stem cells using Cas9 from Neisseria meningitidis. Proc Natl Acad Sci U S A (2013) 3.53
Programmable repression and activation of bacterial gene expression using an engineered CRISPR-Cas system. Nucleic Acids Res (2013) 3.51
Multiplexed activation of endogenous genes by CRISPR-on, an RNA-guided transcriptional activator system. Cell Res (2013) 3.50
Highly efficient RNA-guided genome editing in human cells via delivery of purified Cas9 ribonucleoproteins. Genome Res (2014) 3.31
Saturation editing of genomic regions by multiplex homology-directed repair. Nature (2014) 3.30
The basic principles of chimeric antigen receptor design. Cancer Discov (2013) 3.28
CRISPR-mediated direct mutation of cancer genes in the mouse liver. Nature (2014) 3.28
A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response. Nature (2012) 3.24
In vivo engineering of oncogenic chromosomal rearrangements with the CRISPR/Cas9 system. Nature (2014) 3.15
Non-viral vectors for gene-based therapy. Nat Rev Genet (2014) 3.04
Genetic and physical analysis of double-strand break repair and recombination in Saccharomyces cerevisiae. Genetics (1989) 2.93
Site-specific recombination determined by I-SceI, a mitochondrial group I intron-encoded endonuclease expressed in the yeast nucleus. Genetics (1992) 2.92
Oncogene regulation. An oncogenic super-enhancer formed through somatic mutation of a noncoding intergenic element. Science (2014) 2.91
Cationic lipid-mediated delivery of proteins enables efficient protein-based genome editing in vitro and in vivo. Nat Biotechnol (2014) 2.75
Chromosomal deletions and inversions mediated by TALENs and CRISPR/Cas in zebrafish. Nucleic Acids Res (2013) 2.73
Enhanced homology-directed human genome engineering by controlled timing of CRISPR/Cas9 delivery. Elife (2014) 2.65
Modeling colorectal cancer using CRISPR-Cas9-mediated engineering of human intestinal organoids. Nat Med (2015) 2.43
A protein-tagging system for signal amplification in gene expression and fluorescence imaging. Cell (2014) 2.27
Characterization of genomic deletion efficiency mediated by clustered regularly interspaced palindromic repeats (CRISPR)/Cas9 nuclease system in mammalian cells. J Biol Chem (2014) 2.18
MLL3 is a haploinsufficient 7q tumor suppressor in acute myeloid leukemia. Cancer Cell (2014) 1.98
Rapid modelling of cooperating genetic events in cancer through somatic genome editing. Nature (2014) 1.86
Non-germline genetically engineered mouse models for translational cancer research. Nat Rev Cancer (2010) 1.80
Chromosomal translocations in human cells are generated by canonical nonhomologous end-joining. Mol Cell (2014) 1.72
Targeted genomic rearrangements using CRISPR/Cas technology. Nat Commun (2014) 1.70
Safe harbours for the integration of new DNA in the human genome. Nat Rev Cancer (2011) 1.67
Inducible in vivo genome editing with CRISPR-Cas9. Nat Biotechnol (2015) 1.64
Use of the CRISPR/Cas9 system to produce genetically engineered pigs from in vitro-derived oocytes and embryos. Biol Reprod (2014) 1.64
Engineering human tumour-associated chromosomal translocations with the RNA-guided CRISPR-Cas9 system. Nat Commun (2014) 1.43
Generation of mouse models of myeloid malignancy with combinatorial genetic lesions using CRISPR-Cas9 genome editing. Nat Biotechnol (2014) 1.43
Repurposing CRISPR/Cas9 for in situ functional assays. Genes Dev (2013) 1.41
Simple and rapid in vivo generation of chromosomal rearrangements using CRISPR/Cas9 technology. Cell Rep (2014) 1.30
Megabase-scale deletion using CRISPR/Cas9 to generate a fully haploid human cell line. Genome Res (2014) 1.28
Targeting non-coding RNAs with the CRISPR/Cas9 system in human cell lines. Nucleic Acids Res (2014) 1.26
Efficient in vivo deletion of a large imprinted lncRNA by CRISPR/Cas9. RNA Biol (2014) 1.16
Life in the fast lane: mammalian disease models in the genomics era. Cell (2012) 1.08